The FDA approved ribocilib (Kisqali; Novartis) with an aromatase inhibitor (AI) for breast cancer patients with HR-positive, HER2-negative stage II and III early breast cancer at high risk of ...
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts.
Search for other works by this author on: ...
Search for other works by this author on: ...
Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia.
Division of Cell Signaling and Metabolism, German Cancer Research Center (DKFZ) and DKFZ-ZMBH Alliance, Heidelberg, Germany.
Adding the PD-1 inhibitor pembrolizumab to chemoradiotherapy for high-risk, locally advanced cervical cancer significantly improves patients’ overall survival compared to treatment with CRT alone.
University of Nebraska Medical Center, Omaha, NE, ...
According to the phase IIIb/IV DESTINYBreast-12 Trial, the results of which were presented at the European Society for Medical Oncology 2024 Congress in Barcelona, Spain, and concurrently published, ...
Which manuscripts qualify for the simultaneous publication opportunity? Any manuscripts on the same topic as the author’s submitted abstract, and that are submitted by the deadlines noted below, will ...
This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. This work is licensed under a Creative Commons ...
Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback